A detailed history of Victory Capital Management Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 27,394 shares of RXRX stock, worth $189,292. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,394
Previous 21,891 25.14%
Holding current value
$189,292
Previous $164,000 9.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$5.92 - $8.6 $32,577 - $47,325
5,503 Added 25.14%
27,394 $180,000
Q2 2024

Aug 05, 2024

BUY
$7.35 - $10.05 $19,095 - $26,109
2,598 Added 13.47%
21,891 $164,000
Q1 2024

May 03, 2024

SELL
$9.13 - $15.52 $10,481 - $17,816
-1,148 Reduced 5.62%
19,293 $192,000
Q4 2023

Feb 05, 2024

BUY
$5.09 - $10.79 $26,442 - $56,054
5,195 Added 34.07%
20,441 $201,000
Q3 2023

Nov 06, 2023

BUY
$6.59 - $15.86 $19,190 - $46,184
2,912 Added 23.61%
15,246 $116,000
Q2 2023

Jul 27, 2023

SELL
$4.56 - $9.94 $1,313 - $2,862
-288 Reduced 2.28%
12,334 $92,000
Q1 2023

May 02, 2023

SELL
$6.42 - $9.64 $3,691 - $5,543
-575 Reduced 4.36%
12,622 $84,000
Q4 2022

Feb 10, 2023

BUY
$7.16 - $12.7 $859 - $1,524
120 Added 0.92%
13,197 $101,000
Q4 2022

Feb 09, 2023

BUY
$7.16 - $12.7 $7,267 - $12,890
1,015 Added 8.41%
13,077 $100,000
Q3 2022

Nov 02, 2022

BUY
$7.83 - $13.6 $94,445 - $164,043
12,062 New
12,062 $128,000
Q3 2021

Nov 02, 2021

SELL
$19.03 - $41.33 $125,978 - $273,604
-6,620 Closed
0 $0
Q2 2021

Aug 03, 2021

BUY
$18.0 - $37.42 $119,160 - $247,720
6,620 New
6,620 $242,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.